Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are unusual and rare epithelial tumors for which the diagnosis of the grade of malignancy and prognostic assessment on the basis ofhistology represent considerable challenges for the pathologist. In this study we conducted a retrospective analysis of the cell proliferation (Ki-67 nuclear antigen) in primary and metastatic GEP NENs of 137 patients as well as the assessment of keratin 19 (CKI9) and progesterone receptors (PR) expression in pancreatic NENs of 57 patients. In 19 (27,1%) GEP NEN metastases was found I,5-4,5-fold increase of Ki-67 index compared with their primaries. Consequently, 6 (21,4%) cases of NETGI and 4 (7,0%) cases of NET G2 were up-graded Pancreatic NETs G2 with Ki-67 index >5% were significantly associated with presence of distant metastases (p =0,007) and decreased survival (p=0,03). Decreased survival also was found in the group of gastrointestinal NET G2 with Ki-67 index > 15% (p=0,005). Further analysis of immunomorphological features and proliferative activity allowed to separate a rare group of tumors - ("NET G3", characterized by decreased survival comparing to NET G2. Expression of CKI9 in pancreatic NETs was significantly associated with higher proliferative activity of primary tumor (p =0,04) and adverse outcome (p=0,003). On other hand, PR expression correlated with lower Ki-67 index (p=0,006), absence of metastases (p=0,004) and favorable outcome (p=0,000). Our results show that Ki67 index is a key parameter of morphological diagnosis of GEP NENs. Thus, the studied markers are important parameters of the morphological diagnostic of GEP NENs, which allow more accurately assess the degree of malignancy, prognosis and treatment of the disease.
Download full-text PDF |
Source |
---|
Rev Endocr Metab Disord
December 2024
Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sapienza University of Rome, Rome, Italy.
Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs.
View Article and Find Full Text PDFClin Med Insights Oncol
December 2024
Department of Pathology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of neoplasms with an increasing incidence in the last few decades. Despite therapeutic advances in the management of GEP-NENs, resistance to many of these treatments has made their management a great challenge. One of the most recent advances in oncologic therapy is targeting multiple receptors simultaneously and engaging immune cells in the tumor microenvironment through bispecific antibodies (BsAbs).
View Article and Find Full Text PDFEJNMMI Res
November 2024
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Neuroendocrinology
November 2024
Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy.
Introduction: Lu-PRRT in neuroendocrine tumors is usually delivered with a total cumulative activity (TCA) of 29.6 GBq, divided into 4 cycles and with fixed interval between cycles (IBCs) of 8 weeks. Based on previous radiobiological studies, reducing IBC could improve efficacy without increasing toxicity.
View Article and Find Full Text PDFFront Oncol
October 2024
Department of Pathology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Objective: Diagnosis and treatment of gastroenteropancreatic high-grade neuroendocrine neoplasms (GEP-HG-NENs), particularly G3 well-differentiated neuroendocrine tumours (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) relies on histopathological morphology, immunohistochemistry, and molecular biological markers, which are lacking especially in cases with ambiguous histomorphology. In this study to contribute to the development of more targeted treatment strategies, we examined various immunohistochemical and molecular biological markers and their association with clinicopathological features in GEP-HG-NENs.
Methods: We included 38 patients with GEP-HG-NENs in this study, with their retrospective follow-up data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!